Title for MeetingAbstracts
Alphabetical listing of titles
Safety and immunogenicity of live recombinant ALVAC-HIV (vCP 1521) priming with gp 120 boosting in Thai HIV seronegative adults.
Safety and immunogenicity of live recombinant ALVAC-HIV (vCP1521) priming with AIDSVAX B/E gp120 boosting in Thai HIV-negative adults.
Safety and immunogenicity of live recombinant ALVAC-HIV (vCP1521) priming with an oligomeric gp160 boost in Thai HIV-seronegative adults.
Safety and Immunogenicity of MenC-CRM197 Conjugate Vaccine Administered as a Primary or Booster Vaccination to Healthy 4-Year Old Children.
Safety and immunogenicity of MN and IIIB rgp 120/HIV-1 vaccines in HIV-1 infected subjects with CD4 counts > 500 cells/mm3.
Safety and immunogenicity of MN/BRU-rgp160 followed with a MN-V3 synthetic peptide in HIV negative volunteers (ANRS VACO2).
Safety and Immunogenicity of Monovalent Meningococcal OMP Vesicle Vaccines in Toddlers.
Safety and Immunogenicity of One Dose of a Tetravalent Pneumococcal Conjugate Vaccine in Young Healthy Adults.
Safety and Immunogenicity of Pneumococcal Conjugate Vaccine (PCV) and Routine Pediatric Immunizations in HIV+ Children on HAART (PACTG P1024).
Safety and immunogenicity of preexposure rabies immunization in HIV-infected children.
Safety and immunogenicity of recombinant envelope HIV vaccines in asymptomatic HIV infected children.
Safety and immunogenicity of recombinant envelope HIV vaccines in asymptomatic HIV-infected children.
Safety and immunogenicity of recombinant outer surface Protein-A Lyme Vaccine in HIV infected patients: Evaluation of a 3-dose schedule at 0,1,and 2 months.
Safety and immunogenicity of rgp160 in accelerated dose schedules.
Safety and immunogenicity study of vCP1452/rgp160 therapeutic vaccines in patients treated with HAART for over two years.
Safety and immunogenicity study on vCP1452/gp160 vaccine in patients treated with HAART for over two years.
Safety and immunogenity of HIV recombinant envelope vaccines in HIV-infected infants and children.
SAFETY AND IMMUNOLOGICAL EFFECTIVENESS OF SIMPLIFIED FIXED-DOSE COMBINATION OF NEVIRAPINE-BASED HAART AMONGST INDIAN PATIENTS: EXTENDED FOLLOW-UP DATA.
Safety and immunomodulatory properties of Tucaresol in HIV-infected patients.
Safety and in vitro efficacy of a topical microbicide gel for the prevention of HIV-1 transmission.
Safety and Long-Term Durability of the Silver Iontophoretic Catheter in an Animal Model.
Safety and Long-Term Effects of Therapy with Radioactively Labeled Antibodies in a Murine Model of Cryptococcus neoformans Infection.
Safety and pharmacokinetic interaction of sorivudine (BV- araU) and zidovudine.
Safety and Pharmacokinetics (PK) of Nelfinavir (NFV) when administered with Stavudine (d4T) and Didanosine (ddI) in HIV-exposed newborn infants.
Safety and pharmacokinetics (pk) of Nevirapine (NVP) in HIV-1 infected pregnant women and their newborns.
Safety and pharmacokinetics (pk) of nevirapine (NVP) in HIV-I infected pregnant women and their newborns. ACTG Protocol 250 Team. American Pediatric Association and Society for Pediatric Research annual meeting; 1996 May 6-10; Washington, D.C.
Safety and pharmacokinetics (Pk) of nevirapine (NVP) in neonates born to HIV-1 infected women.
Safety and pharmacokinetics (PK) of stavudine (d4T) in hepatic impairment.
Safety and pharmacokinetics (PK) of stavudine (d4T) in subjects with mild, moderate or severe renal impairment.
Safety and pharmacokinetics of an orally bioavailable prodrug of cyclic HPMPC, a potent antiherpes nucleotide analog.